{"ticker": {"uuid": "7931a8da-29c8-4dbe-a5df-c1d22aeb9af2", "symbol": "VYGR", "name": "Voyager Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8", "summary": "Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its target price at $8. This indicates the firm's continued confidence in the company's financial performance or future prospects.", "url": "https://www.moomoo.com/news/post/72952880/wedbush-maintains-voyager-therapeutics-vygrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-15T00:20:41", "published_display": "15 Jul 2026 00:20", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12", "summary": "CCORF has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $12. This indicates a continued positive outlook on the company's stock performance from the analyst.", "url": "https://www.moomoo.com/news/post/72931953/ccorf-maintains-voyager-therapeutics-vygrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-14T16:12:19", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early", "summary": "Voyager Therapeutics' stock has recently dropped 10%, yet insiders who sold US$405k worth of stock over the past year might have sold too early, as their average selling price of US$3.79 is still below the current share price of US$3.24. Although insider selling occurred at a pri", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vygr/voyager-therapeutics/news/voyager-therapeutics-drops-to-us324-yet-insiders-may-have-so", "source_name": "Simply Wall Street", "published_at": "2026-07-14T11:28:00", "published_display": "14 Jul 2026 11:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer\u2019s Disease Expected H2 2026", "summary": "Voyager Therapeutics announced positive six-month GLP toxicology data for its investigational gene therapy VY1706, showing it was well-tolerated and reduced tau protein by up to 75% in non-human primates after a single intravenous dose. The company received FDA IND clearance for ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326162/36461/en/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-month-glp-toxicology-study-initiation-of-clinical-trial-in-alzheimer-s-disease-expected-h2-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T00:20:40", "published_display": "14 Jul 2026 00:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager reports VY1706 Alzheimer\u2019s therapy data", "summary": "Voyager Therapeutics reported positive six-month toxicology results for its investigational Alzheimer\u2019s gene therapy, VY1706, showing significant reductions in tau protein levels in non-human primates. The therapy was well-tolerated, and the FDA has cleared Voyager's IND applicat", "url": "https://grafa.com/en/news/united-states/voyager-vy1706-alzheimers-gene-therapy-results", "source_name": "grafa.com", "published_at": "2026-07-13T17:41:42", "published_display": "13 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager presents six-month data for Alzheimer\u2019s gene therapy", "summary": "Voyager Therapeutics Inc. presented positive six-month toxicology data for its investigational gene therapy VY1706 for Alzheimer's disease at a conference in London. The data showed that VY1706 significantly reduced tau protein in non-human primates and was well tolerated. The co", "url": "https://m.uk.investing.com/news/stock-market-news/voyager-presents-sixmonth-data-for-alzheimers-gene-therapy-93CH-4767664?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T16:41:42", "published_display": "13 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdGw5WktKcEY1X0trZTRZbHRxVHVldThmeXIwcXZpc2pVa0hXSzFOczBaYkVza01fLTdPTGhLa1FscjhyZWZtdjY2NVRRTmpDMmc0bWhyMndpcGdWc2pKRWV2dkhsbWJnNXExMVdmN2lPZ0dBdzMyLUNLQUN5X3pHVTNWMjVTem5Fc1NNVldBLWxBNHdfaHVMdDhzZDlFMkNhUGM4SkdqTnotVXZSeUV0VmxxZlJxZVZXbjVZ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T13:05:38+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Voyager Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUkN5eGJKZ1k4SzljTjcwTXlLOUNfeE9mS2lxLXlraFB1eFpIaTZtcWd2ZXlvSkVVR0tOTXBGbjF1emxKa2UycmcxTUVlNzRJRDZqUzRsQU1pX0hXTGNpQlRibGNzWUFRbmN1alNzWGRnT2FmY0dpdjYzb0NWOGgwZFNDenpMWWY0OHpHLXNDTC1BLURTRUs1TW95LUtycGRqc3lMR3FXQWhfdjNtTUh1RFlnZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:44:37+00:00", "published_display": "13 Jul 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/voyager-therapeutics-expects-start-early-123541467.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:35:41+00:00", "published_display": "13 Jul 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Single-dose Alzheimer\u2019s gene therapy from Voyager lowers brain tau in primates", "summary": "Voyager Therapeutics reported positive 6-month GLP toxicology results for its investigational Alzheimer\u2019s gene therapy, VY1706. The single intravenous dose was well tolerated in non-human primates and significantly reduced tau protein by up to 75% in key brain regions. The compan", "url": "https://www.stocktitan.net/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-rgk90rldv4fy.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:41:42", "published_display": "13 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026", "summary": "As of June 30, 2026, Voyager Therapeutics (VYGR) had a short interest of 3.57 million shares, which is 6.78% of its public float, marking a 1.99% decrease from the previous report. The short interest ratio is 5.1 days to cover. The article provides detailed historical short inter", "url": "https://www.marketbeat.com/stocks/NASDAQ/VYGR/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T23:41:42", "published_display": "10 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase", "summary": "Voyager Therapeutics, a clinical-stage biotechnology company, is focused on developing gene therapies for serious neurological diseases, particularly targeting conditions of the central nervous system using AAV-based therapies. The company employs a business model that combines i", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/voyager-therapeutics-outlines-gene-therapy-pipeline-clinical-partnerships/69723888", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:02:00", "published_display": "08 Jul 2026 15:02", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets", "summary": "Voyager Therapeutics is advancing a neurology-focused gene therapy pipeline, utilizing its CNS delivery technology to develop treatments for severe neurological conditions. The company's strategy involves both internal development and collaborations with larger pharmaceutical par", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/voyager-therapeutics-outlines-its-gene-therapy-pipeline-investors-focus/69717266", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:39:00", "published_display": "07 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYGR - Voyager Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Voyager Therapeutics Inc (VYGR). It includes detailed financial metrics such as market capitalization, income, sales, P/E ratios, employee count, and stock performance data. The report also highligh", "url": "https://finviz.com/stock?t=VYGR&ty=lf&p=d&b=1&page=20", "source_name": "Finviz", "published_at": "2026-07-04T09:10:13", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics : VYGR", "summary": "This article provides an overview of Voyager Therapeutics Inc (VYGR), a biotechnology firm specializing in gene therapies for neurological diseases like Alzheimer's. It highlights the company's leading project, VY-TAU01, and its collaborations with partners such as Alexion and No", "url": "https://247wallst.com/companies/VYGR/?tpid=1618161&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-02T22:11:09", "published_display": "02 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This article provides the enterprise value to revenue forward for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It confirms that the financial data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a financial data point from Trad", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:41:13", "published_display": "01 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article provides the \"Price to book forward\" financial metric for Voyager Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:VT6. It indicates that the period value and changes are available, sourced from FactSet Research Systems Inc. and ICE Dat", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:54", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "The article focuses on the \"Price to sales forward\" metric for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It serves as a brief financial data point for the company, indicating a specific period, value, and change percentage for this metric. The content itself seems to be a snapsh", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:54", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article displays the \"Price to sales forward\" metric for Voyager Therapeutics, Inc. (FWB:VT6). It includes a table showing the period, value, change, and percentage change for this financial metric. The content itself provides financial data within the TradingView platform.", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T12:10:46", "published_display": "30 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Alzheimer\u2019s gene therapy gets a late-breaking AAIC poster", "summary": "Voyager Therapeutics will present a late-breaking poster on its investigational gene therapy, VY1706, for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in London, July 12\u201315, 2026. This announcement follows the recent FDA IND clearance for VY1", "url": "https://www.stocktitan.net/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-egdn5ivv19em.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:14", "published_display": "30 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQd3B4X1BKanhGN3VDUlctOTRGM094QWxycXlkM2wtdXJreHFRX3ZjNkQ3SEhqajlyODM3WnZmVWRhdlNVRmVacGFaMXF3OXpNYTZieWRCSjZYVjFkTHRwaklpV1VJM2lpNHh5andreldrb29LQVVzNVNOQlJneWcybENyZEN0bXV2QW9XcHFCR1Z3a3NmYUR5Z3dPU09raWdD?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ: VYGR), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data placeholder from TradingView, indicating where detailed financial metrics for the company would be", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:27", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article provides financial information for Voyager Therapeutics, Inc. (FWB:VT6), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data point from a financial platform like TradingView, indicating a value for this metric during", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:27", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Tau-Targeted Gene Therapy VY1706 for Alzheimer\u2019s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/voyager-tau-targeted-gene-therapy-120100830.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:01:00+00:00", "published_display": "29 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to present Alzheimer\u2019s gene therapy data at AAIC By Investing.com", "summary": "Voyager Therapeutics Inc. (NASDAQ:VYGR) is set to present preclinical data for its Alzheimer\u2019s gene therapy, VY1706, at the Alzheimer\u2019s Association International Conference. The company recently received FDA clearance for its Investigational New Drug application and plans to star", "url": "https://m.au.investing.com/news/stock-market-news/voyager-to-present-alzheimers-gene-therapy-data-at-aaic-93CH-4508984?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-29T12:41:54", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Tau-Targeted Gene Therapy VY1706 for Alzheimer\u2019s", "summary": "Voyager Therapeutics announced that its investigational gene therapy, VY1706, for Alzheimer's disease will be featured in a late-breaking poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) in London. The company recently received FDA Inves", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318916/0/en/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-featured-in-developing-topics-poster-presentation-at-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:27", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ:VYGR), specifically focusing on its price-to-book forward ratio. The content is presented within the TradingView platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:16", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to present Alzheimer\u2019s gene therapy data at AAIC", "summary": "Voyager Therapeutics (NASDAQ:VYGR) will present preclinical data for its Alzheimer's disease gene therapy, VY1706, at the Alzheimer's Association International Conference. The company recently received FDA clearance for its Investigational New Drug application for VY1706, which i", "url": "https://www.investing.com/news/company-news/voyager-to-present-alzheimers-gene-therapy-data-at-aaic-93CH-4765243", "source_name": "Investing.com", "published_at": "2026-06-28T11:10:55", "published_display": "28 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYGR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Voyager Therapeutics, Inc. (VYGR) stock, including analyst price targets and ratings. It details the stock's current price, historical performance, financial metrics like earnings and revenue, and upcoming earnings dates. The forecast section ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:39", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR)", "summary": "This article provides an overview of Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock performance, financial actuals and estimates, and analyst forecasts. It details current stock price, volatility, market capitalization, earnings, and revenue, alongside historical highs and lows.", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:57", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) with a $25.00 price target. This follows a previous Buy rating from TD Cowen. The company reported a Q1 revenue of $2.59 million and a net loss of $27.94 million, while corporate insid", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16061/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:05", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6)", "summary": "This article provides an overview of Voyager Therapeutics, Inc. (VT6), including its financial actuals and estimates, stock forecast, and historical price data. It details the company's past earnings and revenue performance, along with analyst predictions for future quarters. The", "url": "https://www.tradingview.com/symbols/MUN-VT6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:51", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), identifying its major shareholders and their respective proportions, such as Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice Capital LLC. It also presents a breakdown of shareholder t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vygr/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:28", "published_display": "19 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $15.38, Implies 325% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWUdpS25BSFlaUGhWU2xFV0J0NENJUU93OWFjc0hrV3ktNjR2MWJWTEZQaXdaYmFwZk0wdHU5NXdhM2FXS3A1UmpEOU9BaG45MVVPUUx1VDNHZ0k3UHB6Ynlha1FuRFNJdFMyN0s3b0VQd3RmWEZBdlNWMWJaOGtTUmpSTXZneUtRUjNHdFU4bmRod3F1WEZSb1BNaXpVTkxNalRKeVI4ZkR5V2dnUnpQc2UwY3o2M2JfVVNXUUNtcGtWM3ZwNVlRNXZfTnhKR205MWF3VHVhMmxJWWNOUHJhcXFyZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/voyager-present-h-c-wainwright-200100765.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:01:00+00:00", "published_display": "11 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSk4xMTRMc0hxMWNFOUh2VkNZWFZPd3gtOFFCTC1xbl81TkFKVzNlLWNFeUtVRHhQU1hCd0hqQzZsMWxYRDRvclBlUl8xZjVPUnZKRDJQeXBMay1NdUhRMzhMMDl6TnF4djR4aXBuOGZLUlF1Wk5RZzkxY3YyTzV5ZkdVRnZEaG4ta005VkdnbUJ5MWtrSE9Lem9GbFgyV1FqRnVwbXdxam1KQldlQTNGODE1RjR6QjNEc0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) director receives 30,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQenI1SjF5OTZib29xMHpoVjNwZ2FERno2X3FDUHdfYTZuYWNPRG1LQlF6VWRQQXEzeEhVYUpvdmJ0YV9Pb05OWHFEMWc0dEx6cW9fZ1JHcW9OOWw0WThnamR1bTN3Vnk0Vi14TENKcF9GLXJoUlNEZjlhcTdLdUFpY0RyNmZMdllmOWVhMHRSQXZzMDJEdnZ6QVRnT0p4S2xJQWpWcEN6LWlsT1lQNFZjLWVOZV9MdVNzY2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s CEO joins H.C. Wainwright neuro conference fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMmplUlduNVUweEYzR0w1NFNHWmp2ckVDY0J2NGRvYWJZZm1WY2FITElDX0I4Sl9jTzVwTUVXRVBRREMyY0oxZ3BkRGNwcHR2dExhZG1VZHNnXzNDOVJpT1lYTXloZ0RueU5wdE9ZMHNZN1BsVXlhZWYtam1INXRFWmd2d1NXRnpMQkE5Y1Byb1NUNXg4YlluQW4yNS1yZHlET19xalJfWHJ5UURLdU9jZ2NmQUdSR01BSWFZQ3VB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNaUJYTzg0Q3lsUXQwbGJVdmpyR1Q4S2JnNUQ2ZzN5bUZRREE3cnZmYjg5ZHlIX1hHcmhLSzA4M2FUSTBtemRVVjdxem0yeEhoTk1aX2xnZXY0V3VhVXdVb3hYRklGSHhXU0E2ZmZlLXdrR19sYzBPSUVQUERJWkdXcDJ1TFhYSWdKNUhXdVJ6WGJuZjBXOVl6M1RNemUyWWQ0cmtwRkVkWDFmWmNjSnQ4SUd2WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPblc3NDVxNmZib2pUdXotNG5BQ1RBQUFUUHgzN21WU2syank1ZkxhQnBuU1dpWWtsSUwzZ2VBeFlLbEd3TENIVjh2aFh1TnZ0TjlMSnBZOFpsdkFxd1FlVERZaTMzY21tSVV5aHgzajZpRXhMSlVuRDNCYmFycG1FYTZjUzd4RW1xLXV2QmNVaEktTnAwemc?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/voyager-receives-fda-ind-clearance-120000853.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZDNlZ2JfVWxQa3BlM0I1NlRxTHVfS1E0NzhnOWJXSkxXbC1sQXhSVV9uSmZBVWk3cU5jaU11N1cxOWNCcWZXaU9OcEZuMTYwaE4yTlJHQk1EOXg5SmpBRldEMXRtMFlkbGVZUFBELUxXU3pHQjNzdWwwMHZlMEtTUTVxMjNfbndqdllxMkZvSGtvTTIxRTF6bGFZMFlvT3BkSEFONFI1VEI?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3AzNG56bG4zNzhUZGxUdkdyTVpUemNpSDM3V09uY1A0OFJsZkJNMGN2ekRIWXlVYzVqU0lWclQ0VGRIVllRUzlDXzdPVXVZRmR3RmlpSkZWVWx3WFBwcUJaTjZSdWpUOWdERlMtZTliclAwOU0wN1Qwd1B2U01PSWt3Q1ZPekJLZ0RLeUh1YlBMRFJNRjk3RlE0anE2SXlleW56NA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPTkw0UXZjVHNoNDdmelUtS0s5ZXNDQW1fekFOMXhwcTVkRGJWTlhpY2RkUkNPTi1qeEx3YURnQUtFVE03aGZwYVBKQ2xteVdWMEFUUFZOUXpzcTNBVzBDems0WnNqd2J6NDI1Rmx4VGZNMVcwNjg2dkRhX1ZwOVFVNW9pNEYxOF9haFIwNHROcjJ4cG9OaC15RWN1Y0NsMXluSG9pNklIZDc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPaFdSbEFfZXJpZUhVQVpZQTl2U3M3OVIxenZPZVpZQ1ctTjhfZldvdTJGT3lPclF1OU9DcXpGUWcyOTEzWlpKMlkzMDl0R2lQanh1MDNrdDhNRXA4Q2lBZU5uV3pabVFremU3a3JuSUo3M19iLWhfc1JwV0o5MWdqS1hWcEpLM2VhNkVGRXcwZUh4cENrR2VnVmEweEYza1B4X09kdlBLcGtLUGo5ZDV4QUNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Voyager Therapeutics\u2019 (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQSlBxcWd0M1BBbzVaeEc1QXUwTy1OVXE1ejhlVkNpdDZpNllYVFhWd3Iwc2NHbHM3QTVsOE9yeUVzakxFSzdnbDQwV3FReUE5WURhOXpqLXFFZnBUYXJlNGN2UWlnTmVPVEV6STZYV1lJT3JRampHTldpdHV4WDl5ZHh1VDlhYXZSYVEzeUZR?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNXM3M0FzWDU4d0xxamVMclhJb3VVY2h4WUxGNjQ0ZEU3bGxCM0NZZ3p0bmVnUEJRbjB0S2NZODd2enY0OXZKSmxyNVA2NDJvbXRFQ2pGVUlQNGRKdFBKRURvR0JBWGFiTF9XQjVaVUlYZmlpcWxIQjlaanZTUnRoZjJPVGRrNm1x?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. (VYGR) Stock Price Today: $3.68", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE0zdHZEMUlBSnJocEpjSmtQNjI1Rkl5V2kzcEZmMHVCLWlxSTBSZ0htNHBwMjdiRjZPMTVqajNpZ0tkc0ZKVjBlaWdLbHhmNTVQSEhwVDlGMA?oc=5", "source_name": "Gotrade", "published_at": "2026-02-05T19:56:34+00:00", "published_display": "05 Feb 2026 19:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Voyager Therapeutics Stock Sliding, Have You Assessed The Risk?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPMV9wZHdFSDJ5SUxJV3V3ZXpCV1NCSWgtRGh3Vk8zZnoyX0RkbG5ITmtEcE5kaTFuMWZtLVJzMzRVdUlRbURUSWxGU24xQ3JkZUNKSHphdDNtUDM1MjFUajN5ajEtUlV6Skh1QnprUm03N3pYbUw0WjdycUJoTHo2UDgxa0pRYW5USGJQb0hyQ1ZSQVdrX1JvQXlZN3dnT1cwajBMMDZCRktTeHhaa1VkczE4U1MxeVJpQ2dhNnpiZndiV3dzQlZZbXl6MkJtX1YtRU9R?oc=5", "source_name": "Trefis", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8", "summary": "Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its target price at $8. This indicates the firm's continued confidence in the company's financial performance or future prospects.", "url": "https://www.moomoo.com/news/post/72952880/wedbush-maintains-voyager-therapeutics-vygrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-15T00:20:41", "published_display": "15 Jul 2026 00:20", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12", "summary": "CCORF has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $12. This indicates a continued positive outlook on the company's stock performance from the analyst.", "url": "https://www.moomoo.com/news/post/72931953/ccorf-maintains-voyager-therapeutics-vygrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-14T16:12:19", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early", "summary": "Voyager Therapeutics' stock has recently dropped 10%, yet insiders who sold US$405k worth of stock over the past year might have sold too early, as their average selling price of US$3.79 is still below the current share price of US$3.24. Although insider selling occurred at a pri", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vygr/voyager-therapeutics/news/voyager-therapeutics-drops-to-us324-yet-insiders-may-have-so", "source_name": "Simply Wall Street", "published_at": "2026-07-14T11:28:00", "published_display": "14 Jul 2026 11:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer\u2019s Disease Expected H2 2026", "summary": "Voyager Therapeutics announced positive six-month GLP toxicology data for its investigational gene therapy VY1706, showing it was well-tolerated and reduced tau protein by up to 75% in non-human primates after a single intravenous dose. The company received FDA IND clearance for ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326162/36461/en/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-month-glp-toxicology-study-initiation-of-clinical-trial-in-alzheimer-s-disease-expected-h2-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T00:20:40", "published_display": "14 Jul 2026 00:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager reports VY1706 Alzheimer\u2019s therapy data", "summary": "Voyager Therapeutics reported positive six-month toxicology results for its investigational Alzheimer\u2019s gene therapy, VY1706, showing significant reductions in tau protein levels in non-human primates. The therapy was well-tolerated, and the FDA has cleared Voyager's IND applicat", "url": "https://grafa.com/en/news/united-states/voyager-vy1706-alzheimers-gene-therapy-results", "source_name": "grafa.com", "published_at": "2026-07-13T17:41:42", "published_display": "13 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager presents six-month data for Alzheimer\u2019s gene therapy", "summary": "Voyager Therapeutics Inc. presented positive six-month toxicology data for its investigational gene therapy VY1706 for Alzheimer's disease at a conference in London. The data showed that VY1706 significantly reduced tau protein in non-human primates and was well tolerated. The co", "url": "https://m.uk.investing.com/news/stock-market-news/voyager-presents-sixmonth-data-for-alzheimers-gene-therapy-93CH-4767664?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T16:41:42", "published_display": "13 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdGw5WktKcEY1X0trZTRZbHRxVHVldThmeXIwcXZpc2pVa0hXSzFOczBaYkVza01fLTdPTGhLa1FscjhyZWZtdjY2NVRRTmpDMmc0bWhyMndpcGdWc2pKRWV2dkhsbWJnNXExMVdmN2lPZ0dBdzMyLUNLQUN5X3pHVTNWMjVTem5Fc1NNVldBLWxBNHdfaHVMdDhzZDlFMkNhUGM4SkdqTnotVXZSeUV0VmxxZlJxZVZXbjVZ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T13:05:38+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Voyager Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUkN5eGJKZ1k4SzljTjcwTXlLOUNfeE9mS2lxLXlraFB1eFpIaTZtcWd2ZXlvSkVVR0tOTXBGbjF1emxKa2UycmcxTUVlNzRJRDZqUzRsQU1pX0hXTGNpQlRibGNzWUFRbmN1alNzWGRnT2FmY0dpdjYzb0NWOGgwZFNDenpMWWY0OHpHLXNDTC1BLURTRUs1TW95LUtycGRqc3lMR3FXQWhfdjNtTUh1RFlnZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:44:37+00:00", "published_display": "13 Jul 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/voyager-therapeutics-expects-start-early-123541467.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:35:41+00:00", "published_display": "13 Jul 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Single-dose Alzheimer\u2019s gene therapy from Voyager lowers brain tau in primates", "summary": "Voyager Therapeutics reported positive 6-month GLP toxicology results for its investigational Alzheimer\u2019s gene therapy, VY1706. The single intravenous dose was well tolerated in non-human primates and significantly reduced tau protein by up to 75% in key brain regions. The compan", "url": "https://www.stocktitan.net/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-rgk90rldv4fy.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:41:42", "published_display": "13 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026", "summary": "As of June 30, 2026, Voyager Therapeutics (VYGR) had a short interest of 3.57 million shares, which is 6.78% of its public float, marking a 1.99% decrease from the previous report. The short interest ratio is 5.1 days to cover. The article provides detailed historical short inter", "url": "https://www.marketbeat.com/stocks/NASDAQ/VYGR/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T23:41:42", "published_display": "10 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase", "summary": "Voyager Therapeutics, a clinical-stage biotechnology company, is focused on developing gene therapies for serious neurological diseases, particularly targeting conditions of the central nervous system using AAV-based therapies. The company employs a business model that combines i", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/voyager-therapeutics-outlines-gene-therapy-pipeline-clinical-partnerships/69723888", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:02:00", "published_display": "08 Jul 2026 15:02", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets", "summary": "Voyager Therapeutics is advancing a neurology-focused gene therapy pipeline, utilizing its CNS delivery technology to develop treatments for severe neurological conditions. The company's strategy involves both internal development and collaborations with larger pharmaceutical par", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/voyager-therapeutics-outlines-its-gene-therapy-pipeline-investors-focus/69717266", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:39:00", "published_display": "07 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYGR - Voyager Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Voyager Therapeutics Inc (VYGR). It includes detailed financial metrics such as market capitalization, income, sales, P/E ratios, employee count, and stock performance data. The report also highligh", "url": "https://finviz.com/stock?t=VYGR&ty=lf&p=d&b=1&page=20", "source_name": "Finviz", "published_at": "2026-07-04T09:10:13", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics : VYGR", "summary": "This article provides an overview of Voyager Therapeutics Inc (VYGR), a biotechnology firm specializing in gene therapies for neurological diseases like Alzheimer's. It highlights the company's leading project, VY-TAU01, and its collaborations with partners such as Alexion and No", "url": "https://247wallst.com/companies/VYGR/?tpid=1618161&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-02T22:11:09", "published_display": "02 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This article provides the enterprise value to revenue forward for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It confirms that the financial data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a financial data point from Trad", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:41:13", "published_display": "01 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article provides the \"Price to book forward\" financial metric for Voyager Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:VT6. It indicates that the period value and changes are available, sourced from FactSet Research Systems Inc. and ICE Dat", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:54", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "The article focuses on the \"Price to sales forward\" metric for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It serves as a brief financial data point for the company, indicating a specific period, value, and change percentage for this metric. The content itself seems to be a snapsh", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:54", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article displays the \"Price to sales forward\" metric for Voyager Therapeutics, Inc. (FWB:VT6). It includes a table showing the period, value, change, and percentage change for this financial metric. The content itself provides financial data within the TradingView platform.", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T12:10:46", "published_display": "30 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Alzheimer\u2019s gene therapy gets a late-breaking AAIC poster", "summary": "Voyager Therapeutics will present a late-breaking poster on its investigational gene therapy, VY1706, for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in London, July 12\u201315, 2026. This announcement follows the recent FDA IND clearance for VY1", "url": "https://www.stocktitan.net/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-egdn5ivv19em.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:14", "published_display": "30 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQd3B4X1BKanhGN3VDUlctOTRGM094QWxycXlkM2wtdXJreHFRX3ZjNkQ3SEhqajlyODM3WnZmVWRhdlNVRmVacGFaMXF3OXpNYTZieWRCSjZYVjFkTHRwaklpV1VJM2lpNHh5andreldrb29LQVVzNVNOQlJneWcybENyZEN0bXV2QW9XcHFCR1Z3a3NmYUR5Z3dPU09raWdD?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ: VYGR), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data placeholder from TradingView, indicating where detailed financial metrics for the company would be", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:27", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Voyager Therapeutics, Inc. \u2013 FWB:VT6", "summary": "This article provides financial information for Voyager Therapeutics, Inc. (FWB:VT6), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data point from a financial platform like TradingView, indicating a value for this metric during", "url": "https://www.tradingview.com/symbols/FWB-VT6/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:27", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Tau-Targeted Gene Therapy VY1706 for Alzheimer\u2019s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/voyager-tau-targeted-gene-therapy-120100830.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:01:00+00:00", "published_display": "29 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to present Alzheimer\u2019s gene therapy data at AAIC By Investing.com", "summary": "Voyager Therapeutics Inc. (NASDAQ:VYGR) is set to present preclinical data for its Alzheimer\u2019s gene therapy, VY1706, at the Alzheimer\u2019s Association International Conference. The company recently received FDA clearance for its Investigational New Drug application and plans to star", "url": "https://m.au.investing.com/news/stock-market-news/voyager-to-present-alzheimers-gene-therapy-data-at-aaic-93CH-4508984?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-29T12:41:54", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s Tau-Targeted Gene Therapy VY1706 for Alzheimer\u2019s", "summary": "Voyager Therapeutics announced that its investigational gene therapy, VY1706, for Alzheimer's disease will be featured in a late-breaking poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) in London. The company recently received FDA Inves", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318916/0/en/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-featured-in-developing-topics-poster-presentation-at-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:27", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Voyager Therapeutics, Inc. \u2013 NASDAQ:VYGR", "summary": "This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ:VYGR), specifically focusing on its price-to-book forward ratio. The content is presented within the TradingView platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:16", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to present Alzheimer\u2019s gene therapy data at AAIC", "summary": "Voyager Therapeutics (NASDAQ:VYGR) will present preclinical data for its Alzheimer's disease gene therapy, VY1706, at the Alzheimer's Association International Conference. The company recently received FDA clearance for its Investigational New Drug application for VY1706, which i", "url": "https://www.investing.com/news/company-news/voyager-to-present-alzheimers-gene-therapy-data-at-aaic-93CH-4765243", "source_name": "Investing.com", "published_at": "2026-06-28T11:10:55", "published_display": "28 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYGR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Voyager Therapeutics, Inc. (VYGR) stock, including analyst price targets and ratings. It details the stock's current price, historical performance, financial metrics like earnings and revenue, and upcoming earnings dates. The forecast section ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:39", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR)", "summary": "This article provides an overview of Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock performance, financial actuals and estimates, and analyst forecasts. It details current stock price, volatility, market capitalization, earnings, and revenue, alongside historical highs and lows.", "url": "https://www.tradingview.com/symbols/NASDAQ-VYGR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:57", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) with a $25.00 price target. This follows a previous Buy rating from TD Cowen. The company reported a Q1 revenue of $2.59 million and a net loss of $27.94 million, while corporate insid", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16061/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:05", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6)", "summary": "This article provides an overview of Voyager Therapeutics, Inc. (VT6), including its financial actuals and estimates, stock forecast, and historical price data. It details the company's past earnings and revenue performance, along with analyst predictions for future quarters. The", "url": "https://www.tradingview.com/symbols/MUN-VT6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:51", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), identifying its major shareholders and their respective proportions, such as Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice Capital LLC. It also presents a breakdown of shareholder t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vygr/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:28", "published_display": "19 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $15.38, Implies 325% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWUdpS25BSFlaUGhWU2xFV0J0NENJUU93OWFjc0hrV3ktNjR2MWJWTEZQaXdaYmFwZk0wdHU5NXdhM2FXS3A1UmpEOU9BaG45MVVPUUx1VDNHZ0k3UHB6Ynlha1FuRFNJdFMyN0s3b0VQd3RmWEZBdlNWMWJaOGtTUmpSTXZneUtRUjNHdFU4bmRod3F1WEZSb1BNaXpVTkxNalRKeVI4ZkR5V2dnUnpQc2UwY3o2M2JfVVNXUUNtcGtWM3ZwNVlRNXZfTnhKR205MWF3VHVhMmxJWWNOUHJhcXFyZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/voyager-present-h-c-wainwright-200100765.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:01:00+00:00", "published_display": "11 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSk4xMTRMc0hxMWNFOUh2VkNZWFZPd3gtOFFCTC1xbl81TkFKVzNlLWNFeUtVRHhQU1hCd0hqQzZsMWxYRDRvclBlUl8xZjVPUnZKRDJQeXBMay1NdUhRMzhMMDl6TnF4djR4aXBuOGZLUlF1Wk5RZzkxY3YyTzV5ZkdVRnZEaG4ta005VkdnbUJ5MWtrSE9Lem9GbFgyV1FqRnVwbXdxam1KQldlQTNGODE1RjR6QjNEc0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) director receives 30,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQenI1SjF5OTZib29xMHpoVjNwZ2FERno2X3FDUHdfYTZuYWNPRG1LQlF6VWRQQXEzeEhVYUpvdmJ0YV9Pb05OWHFEMWc0dEx6cW9fZ1JHcW9OOWw0WThnamR1bTN3Vnk0Vi14TENKcF9GLXJoUlNEZjlhcTdLdUFpY0RyNmZMdllmOWVhMHRSQXZzMDJEdnZ6QVRnT0p4S2xJQWpWcEN6LWlsT1lQNFZjLWVOZV9MdVNzY2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager\u2019s CEO joins H.C. Wainwright neuro conference fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMmplUlduNVUweEYzR0w1NFNHWmp2ckVDY0J2NGRvYWJZZm1WY2FITElDX0I4Sl9jTzVwTUVXRVBRREMyY0oxZ3BkRGNwcHR2dExhZG1VZHNnXzNDOVJpT1lYTXloZ0RueU5wdE9ZMHNZN1BsVXlhZWYtam1INXRFWmd2d1NXRnpMQkE5Y1Byb1NUNXg4YlluQW4yNS1yZHlET19xalJfWHJ5UURLdU9jZ2NmQUdSR01BSWFZQ3VB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNaUJYTzg0Q3lsUXQwbGJVdmpyR1Q4S2JnNUQ2ZzN5bUZRREE3cnZmYjg5ZHlIX1hHcmhLSzA4M2FUSTBtemRVVjdxem0yeEhoTk1aX2xnZXY0V3VhVXdVb3hYRklGSHhXU0E2ZmZlLXdrR19sYzBPSUVQUERJWkdXcDJ1TFhYSWdKNUhXdVJ6WGJuZjBXOVl6M1RNemUyWWQ0cmtwRkVkWDFmWmNjSnQ4SUd2WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPblc3NDVxNmZib2pUdXotNG5BQ1RBQUFUUHgzN21WU2syank1ZkxhQnBuU1dpWWtsSUwzZ2VBeFlLbEd3TENIVjh2aFh1TnZ0TjlMSnBZOFpsdkFxd1FlVERZaTMzY21tSVV5aHgzajZpRXhMSlVuRDNCYmFycG1FYTZjUzd4RW1xLXV2QmNVaEktTnAwemc?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/voyager-receives-fda-ind-clearance-120000853.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZDNlZ2JfVWxQa3BlM0I1NlRxTHVfS1E0NzhnOWJXSkxXbC1sQXhSVV9uSmZBVWk3cU5jaU11N1cxOWNCcWZXaU9OcEZuMTYwaE4yTlJHQk1EOXg5SmpBRldEMXRtMFlkbGVZUFBELUxXU3pHQjNzdWwwMHZlMEtTUTVxMjNfbndqdllxMkZvSGtvTTIxRTF6bGFZMFlvT3BkSEFONFI1VEI?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3AzNG56bG4zNzhUZGxUdkdyTVpUemNpSDM3V09uY1A0OFJsZkJNMGN2ekRIWXlVYzVqU0lWclQ0VGRIVllRUzlDXzdPVXVZRmR3RmlpSkZWVWx3WFBwcUJaTjZSdWpUOWdERlMtZTliclAwOU0wN1Qwd1B2U01PSWt3Q1ZPekJLZ0RLeUh1YlBMRFJNRjk3RlE0anE2SXlleW56NA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPTkw0UXZjVHNoNDdmelUtS0s5ZXNDQW1fekFOMXhwcTVkRGJWTlhpY2RkUkNPTi1qeEx3YURnQUtFVE03aGZwYVBKQ2xteVdWMEFUUFZOUXpzcTNBVzBDems0WnNqd2J6NDI1Rmx4VGZNMVcwNjg2dkRhX1ZwOVFVNW9pNEYxOF9haFIwNHROcjJ4cG9OaC15RWN1Y0NsMXluSG9pNklIZDc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPaFdSbEFfZXJpZUhVQVpZQTl2U3M3OVIxenZPZVpZQ1ctTjhfZldvdTJGT3lPclF1OU9DcXpGUWcyOTEzWlpKMlkzMDl0R2lQanh1MDNrdDhNRXA4Q2lBZU5uV3pabVFremU3a3JuSUo3M19iLWhfc1JwV0o5MWdqS1hWcEpLM2VhNkVGRXcwZUh4cENrR2VnVmEweEYza1B4X09kdlBLcGtLUGo5ZDV4QUNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Voyager Therapeutics\u2019 (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQSlBxcWd0M1BBbzVaeEc1QXUwTy1OVXE1ejhlVkNpdDZpNllYVFhWd3Iwc2NHbHM3QTVsOE9yeUVzakxFSzdnbDQwV3FReUE5WURhOXpqLXFFZnBUYXJlNGN2UWlnTmVPVEV6STZYV1lJT3JRampHTldpdHV4WDl5ZHh1VDlhYXZSYVEzeUZR?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNXM3M0FzWDU4d0xxamVMclhJb3VVY2h4WUxGNjQ0ZEU3bGxCM0NZZ3p0bmVnUEJRbjB0S2NZODd2enY0OXZKSmxyNVA2NDJvbXRFQ2pGVUlQNGRKdFBKRURvR0JBWGFiTF9XQjVaVUlYZmlpcWxIQjlaanZTUnRoZjJPVGRrNm1x?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Therapeutics, Inc. (VYGR) Stock Price Today: $3.68", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE0zdHZEMUlBSnJocEpjSmtQNjI1Rkl5V2kzcEZmMHVCLWlxSTBSZ0htNHBwMjdiRjZPMTVqajNpZ0tkc0ZKVjBlaWdLbHhmNTVQSEhwVDlGMA?oc=5", "source_name": "Gotrade", "published_at": "2026-02-05T19:56:34+00:00", "published_display": "05 Feb 2026 19:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Voyager Therapeutics Stock Sliding, Have You Assessed The Risk?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPMV9wZHdFSDJ5SUxJV3V3ZXpCV1NCSWgtRGh3Vk8zZnoyX0RkbG5ITmtEcE5kaTFuMWZtLVJzMzRVdUlRbURUSWxGU24xQ3JkZUNKSHphdDNtUDM1MjFUajN5ajEtUlV6Skh1QnprUm03N3pYbUw0WjdycUJoTHo2UDgxa0pRYW5USGJQb0hyQ1ZSQVdrX1JvQXlZN3dnT1cwajBMMDZCRktTeHhaa1VkczE4U1MxeVJpQ2dhNnpiZndiV3dzQlZZbXl6MkJtX1YtRU9R?oc=5", "source_name": "Trefis", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 61, "sentiment_summary": {"positive": 18, "negative": 7, "neutral": 36, "score": 56, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 3.44, "latest_week": "2026-07-10", "one_week_move": -9.0, "four_week_move": -1.7, "twelve_week_move": -16.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.639894, "market_dynamics_buy_signal": false, "relative_strength": -25.1975, "fair_value_gap": -40.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.568, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.0% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.0% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8"}], "updated_at": "2026-07-16T06:03:36.089833+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}